Akari Therapeutics (AKTX) Profit After Tax (2014 - 2026)
Akari Therapeutics recorded quarterly Profit After Tax of -$14.5 million in Q1 2026, down 172.84% quarter-over-quarter from -$5.3 million in Q4 2025, and down 290.15% year-over-year from $7.6 million in Q1 2025.
Akari Therapeutics' Profit After Tax history runs 13 years deep, the most recent figure standing at -$14.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 290.15% year-over-year to -$14.5 million; the TTM figure through Mar 2026 stood at -$28.0 million (up 81.8% YoY), while the FY2025 annual figure was -$17.3 million, up 12.6% from the prior year.
- Profit After Tax came in at -$14.5 million for Q1 2026 at Akari Therapeutics, down from -$5.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $5.2 million in Q1 2022 to a low of -$140.0 million in Q4 2024.
- A 5-year average of -$13.2 million and a median of -$4.1 million in 2023 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax jumped 188.66% in 2022 and slumped 3283.11% in 2024, its largest moves.
- Akari Therapeutics' Profit After Tax stood at -$5.7 million in 2022, then grew by 27.15% to -$4.1 million in 2023, then plunged by 3283.11% to -$140.0 million in 2024, then surged by 96.22% to -$5.3 million in 2025, then slumped by 172.84% to -$14.5 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$14.5 million, -$5.3 million, and -$6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.46 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -1.90 Mn |
| Mar 31, 2025 | -3.71 Mn |
| Dec 31, 2024 | -139.99 Mn |
| Sep 30, 2024 | -2.90 Mn |
| Jun 30, 2024 | -7.56 Mn |
| Mar 31, 2024 | -5.57 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Sep 30, 2023 | -2.87 Mn |
| Jun 30, 2023 | -4.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Jun 30, 2022 | -5.68 Mn |
| Mar 31, 2022 | -5.18 Mn |
| Dec 31, 2021 | 11.62 Mn |
| Sep 30, 2021 | -1.45 Mn |
| Jun 30, 2021 | -4.35 Mn |
| Mar 31, 2021 | -5.84 Mn |
| Dec 31, 2020 | -6.81 Mn |
| Sep 30, 2020 | 913,454.00 |
| Jun 30, 2020 | -7.44 Mn |
| Mar 31, 2020 | -3,745.41 Bn |
| Dec 31, 2019 | -7.83 Mn |
| Sep 30, 2019 | -2.88 Mn |
| Jun 30, 2019 | -5.95 Mn |
| Mar 31, 2019 | 2.55 Mn |
| Dec 31, 2018 | -3.51 Mn |
| Sep 30, 2018 | -3.59 Mn |
| Jun 30, 2018 | -8.02 Mn |
| Mar 31, 2018 | -1.34 Mn |
| Dec 31, 2017 | -12.12 Mn |
| Sep 30, 2017 | -10.38 Mn |
| Jun 30, 2017 | -320,016.00 |
| Mar 31, 2017 | -12.58 Mn |
| Dec 31, 2016 | -8.29 Mn |
| Sep 30, 2016 | -418,116.00 |
| Jun 30, 2016 | -6.45 Mn |
| Mar 31, 2016 | -2.99 Mn |
| Dec 31, 2015 | 6.47 Mn |
| Sep 30, 2015 | -48.74 Mn |
| Jun 30, 2015 | -1.34 Mn |
| Mar 31, 2015 | -1.70 Mn |
| Dec 31, 2014 | -1.11 Mn |
| Sep 30, 2014 | -223,129.00 |
| Jun 30, 2014 | -2.23 Mn |
| Mar 31, 2014 | -1.74 Mn |